Targeting human langerin promotes HIV-1 specific humoral immune responses

The main avenue for the development of an HIV-1 vaccine remains the induction of protective antibodies. A rationale approach is to target antigen to specific receptors on dendritic cells (DC) via fused monoclonal antibodies (mAb). In mouse and non-human primate models, targeting of skin Langerhans c...

Descripción completa

Detalles Bibliográficos
Autores principales: Kervevan, Jérôme, Bouteau, Aurélie, Lanza, Juliane S., Hammoudi, Adele, Zurawski, Sandra, Surenaud, Mathieu, Dieudonné, Lydie, Bonnet, Marion, Lefebvre, Cécile, Hocini, Hakim, Marlin, Romain, Guguin, Aurélie, Hersant, Barbara, Hermeziu, Oana, Menu, Elisabeth, Lacabaratz, Christine, Lelièvre, Jean-Daniel, Zurawski, Gerard, Godot, Véronique, Henri, Sandrine, Igyártó, Botond Z., Levy, Yves, Cardinaud, Sylvain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354475/
https://www.ncbi.nlm.nih.gov/pubmed/34324611
http://dx.doi.org/10.1371/journal.ppat.1009749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354475/
https://www.ncbi.nlm.nih.gov/pubmed/34324611
http://dx.doi.org/10.1371/journal.ppat.1009749

Ejemplares similares